Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
March 07, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
March 06, 2023 07:02 ET
|
Ocugen
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 07:00 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Completed retinitis pigmentosa patient enrollment in OCU400 Phase 1/2 clinical trial Continued progress for programs targeting eye diseases with the...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
February 27, 2023 17:57 ET
|
Ocugen
MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023 16:30 ET
|
Ocugen
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 01, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 31, 2023 08:00 ET
|
Ocugen
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023 06:00 ET
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022 06:30 ET
|
Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...